Global Oncology Academy
The Global Oncology Academy (GOA) is an educational platform for physicians and other healthcare professionals involved in oncology. Its mission is to increase knowledge regarding the disease course of specific cancers and address key elements for successful management. The GOA series will also share the science around innovations in combination therapies, oncology strategies, and new developments.
For more information about GOA, visit www.globaloncologyacademy.org.
61-75 of 422
Key Differences in Pulmonary and Extrapulmonary NEC Management
Project Oncology®Key Differences in Pulmonary and Extrapulmonary NEC Management
Alexandria May, PharmD, BCPS
Lowell B. Anthony, MD, FACP
DESTINY-Breast11: Trastuzumab Deruxtecan Followed by THP Yields New Indication in the Neoadjuvant Setting.
Oncology and HematologyDESTINY-Breast11: Trastuzumab Deruxtecan Followed by THP Yields New Indication in the Neoadjuvant Setting.
Sara A. Hurvitz, MD, FACP
Evolving epNEC Care: From Default Regimens to Precision-Driven Strategies
Project Oncology®Evolving epNEC Care: From Default Regimens to Precision-Driven Strategies
Alexandria May, PharmD, BCPS
Chandrikha Chandrasekharan, MBBS
TROPION-Breast02: Evidence for the Approval of Datopotamab Deruxtecan for Patients With mTNBC Ineligible for Immunotherapy
Oncology and HematologyTROPION-Breast02: Evidence for the Approval of Datopotamab Deruxtecan for Patients With mTNBC Ineligible for Immunotherapy
Tiffany Traina, MD
Navigating Classification of High-Grade Neuroendocrine Neoplasms
Project Oncology®Navigating Classification of High-Grade Neuroendocrine Neoplasms
Charles Turck, PharmD, BCPS, BCCCP
Rohit Thummalapalli, MD
Optimizing Treatment Intensity in Early-Stage TNBC
Project Oncology®Optimizing Treatment Intensity in Early-Stage TNBC
Roberto Leon-Ferre, MD
- advertisement
DPYD Testing Before Fluoropyrimidine Therapy: Benefits, Risks, and Guidance
Project Oncology®DPYD Testing Before Fluoropyrimidine Therapy: Benefits, Risks, and Guidance
Daniel Hertz, PhD, PharmD
Advancing Cancer Care: Key Considerations for Subcutaneous Immunotherapies
Project Oncology®Advancing Cancer Care: Key Considerations for Subcutaneous Immunotherapies
Charles Turck, PharmD, BCPS, BCCCP
Matthew Hadfield, MD
Emerging TNBC Research: Biomarkers, Genomics, and Adaptive Treatment
Project Oncology®Emerging TNBC Research: Biomarkers, Genomics, and Adaptive Treatment
Roberto Leon-Ferre, MD
Optimizing Quality & Safety Systems to Reduce the Risk of Patient Harm
Project Oncology®Optimizing Quality & Safety Systems to Reduce the Risk of Patient Harm
Jacob Sands, MD
Joseph O. Jacobson, MD
Screening Modalities for Colon Cancer: What You Need to Know
GI InsightsScreening Modalities for Colon Cancer: What You Need to Know
Peter Buch, MD, FACG, AGAF, FACP
Aasma Shaukat, MD, MPH
Breast Cancer Survivorship: Why Lifestyle Medicine Matters
Project Oncology®Breast Cancer Survivorship: Why Lifestyle Medicine Matters
Amy Comander, MD
- advertisement
Navigating NUT Carcinoma: Diagnosis and Treatment Strategies
Project Oncology®Navigating NUT Carcinoma: Diagnosis and Treatment Strategies
Jacob Sands, MD
Jia Luo, MD
Implementing Lifestyle Medicine in Breast Cancer Survivorship Care
Project Oncology®Implementing Lifestyle Medicine in Breast Cancer Survivorship Care
Amy Comander, MD
Matching TNBC Treatment Intensity to Patient Needs
Project Oncology®Matching TNBC Treatment Intensity to Patient Needs
Roberto Leon-Ferre, MD
